VeraChem is pleased to announce the release of VM2 3.0, the latest version of its software for the calculation of protein-ligand and host-guest binding free energies.

VM2 3.0 includes an end-to-end workflow capability that automates system setup and forcefield typing/parameter assignment, ligand 2D to 3D conversion, generation of initial receptor-ligand conformations, submission of free energy calculations via resource managers, and collection and organization of final binding free energy results. Extensive benchmarking of VM2 3.0 predicted binding free...

VeraChem’s development team present the VM2 protein-ligand binding free energy method at Janssen Pharmaceutical

VeraChem’s development team carry out a presentation of the VM2 protein-ligand binding free energy method at Janssen Pharmaceutical, and make agreement for trial usage of the VM2 software package.

VeraChem’s development team carry out presentation of the VM2 protein-ligand binding free energy method at Dart NeuroScience

VeraChem’s development team carry out a presentation of the VM2 protein-ligand binding free energy method at Dart NeuroScience LLC, and make agreement for trial usage of the VM2 software package.

VeraChem software now licensed to over 500 academic researchers worldwide

VeraChem software now licensed to over 500 academic researchers worldwide

VeraChem’s software now licensed to over 500 academic researchers worldwide.

VeraChem licenses its software

VeraChem licenses its software

VeraChem licenses its novel protein-ligand binding affinity software to a major pharmaceutical company.